Biomerica (BMRA) Debt to Equity (2011 - 2012)

Biomerica's (BMRA) quarterly Debt to Equity came in at $0.01 in Q2 2012, up 5.68% year-on-year from $0.01 in Q2 2011, and up 242.23% quarter-over-quarter from $0.0 in Q4 2011.

Biomerica (BMRA) Debt to Equity (2011 - 2012) Analysis & Trends

Biomerica has disclosed Debt to Equity across 2 years of filings, most recently posting $0.01 for Q2 2012.

  • Debt to Equity for Q2 2012 came in at $0.01, up 5.68% year-over-year; the trailing twelve-month figure through May 2012 was $0.01 (up 5.68% YoY), and the FY2012 annual result was $0.01, up 5.68% from the prior year.
  • Debt to Equity came in at $0.01 for Q2 2012 at Biomerica, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.01 in Q2 2012 to a low of $0.0 in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn 0.65
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 0.64
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 0.57
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 0.71
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn 0.95
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn 0.27
10 Biomerica 5.57 Mn 4.23 Mn -44,000.00 -

Historic Data

Download Data
DateValue
May 31, 2012 0.01
Nov 30, 2011 0.00
Aug 31, 2011 0.01
May 31, 2011 0.01